The GSK oncology products it has sold on to Novartis were worth approximately $2 billion in 2014, having posted a growth of around 32 per cent compared to the previous year. The drugs include ...

products which all lag behind the leaders in their particular cancer sub-types, but which Novartis will aim to revive, using its proven track record in oncology franchise management. Meanwhile GSK ...

Last year, Novartis agreed to buy U.S.-based Mariana Oncology for $1 billion upfront to expand its portfolio of the drugs, which currently include prostate cancer treatment Pluvicto and Lutathera ...